Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Next Previous
X
Search
Trial Profile

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorolanib (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms LUGANO
  • Sponsors EyePoint Pharmaceuticals

    • Most Recent Events

    • 05 Mar 2025 According to an EyePoint Pharmaceuticals media release, company on-track to complete enrollment of both trials in the second half of 2025 with topline data anticipated in 2026.
    • 05 Mar 2025 According to an EyePoint Pharmaceuticals media release, trial is over 50% enrolled.
    • 13 Jan 2025 According to an EyePoint Pharmaceuticals media release, Enrollment completion of l Phase 3 LUGANO and LUCIA pivotal trialstrials is expected in 2H 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top